Research Topics
Genomes and GenesSpecies | Sergio AmadoriSummaryAffiliation: Catholic University Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo ItaS Amadori
Department of Hematology, University Tor Vergata, Rome, Italy
Leukemia 19:1768-73. 2005..05). We conclude that the dose/schedule of gemtuzumab ozogamicin used in this trial is too toxic in the age group over 75 years. For these patients, additional studies with reduced doses of the immunotoxin are warranted...
Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 studySergio Amadori
Department of Hematology, University Tor Vergata, St Eugenio Hospital, P le dell Umanesimo, 10, 00144 Rome, Italy
Blood 106:27-34. 2005..2 vs 29.7 days; P < .001). We conclude that although priming with G-CSF can improve the CR rate, the use of G-CSF during and/or after chemotherapy has no effect on the long-term outcome of AML in older patients...- Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groupsSergio Amadori
Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
Haematologica 89:950-6. 2004..The aim of this collaborative trial was to assess the feasibility, safety, and antileukemic activity of administering GO followed by conventional chemotherapy as first line therapy in patients aged 61-75 years with AML... - Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrowLuca Maurillo
Dept of Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
Haematologica 92:605-11. 2007..In the present study, we investigated whether peripheral blood (PB) could be an alternative source of cells for monitoring MRD in AML... 
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemiaLuca Maurillo
Hematology, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
J Clin Oncol 26:4944-51. 2008..The effects of autologous (AuSCT) or allogeneic stem-cell transplantation (SCT) are still under evaluation. Minimal residual disease (MRD) states may be essential for assigning patients to therapy-dependent risk categories...- Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10Franco Mandelli
Department of Cellular Biotechnologies and Hematology, SapienzaUniversity, Rome, Italy
J Clin Oncol 27:5397-403. 2009..To compare the antitumor efficacy of three different anthracyclines in combination with cytarabine and etoposide in adult patients with newly diagnosed acute myeloid leukemia (AML)... - Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemiaGiovanni Del Poeta
Department of Hematology, University Tor Vergata, S Eugenio Hospital, Rome, Italy
Cancer 112:119-28. 2008.... - Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemiaAdriano Venditti
Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10, 00144 Rome, Italy
Haematologica 89:934-9. 2004..The objective of this study was to investigate the expression of MDR1 and bcl-2 proteins in de novo acute myeloid leukemia (AML)... - The genotype nucleophosmin mutated and FLT3-ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemiaGiovanni Del Poeta
Department of Haematology, Ospedale S Eugenio, University Tor Vergata, Rome, Italy
Br J Haematol 149:383-7. 2010..35 subset showed a very high CR rate (96%), very long OS (P = 0.00005) and disease-free survival (P = 0.004). The favourable prognosis of NPM1-mt/FLT3-ITD negative patients might be explained by a higher bax/bcl-2 ratio... - Mucositis in patients with hematologic malignancies: an overviewPasquale Niscola
Haematology Division, Sant Eugenio Hospital and University Tor Vergata, Rome, Italy
Haematologica 92:222-31. 2007..Nevertheless, in the last decade, a better insight into the pathogenesis of the mucosal damage has led to the development of novel therapeutic options which potentially could allow a targeted approach to mucositis... - Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemiaGiovanni Del Poeta
Department of Hematology, University Tor Vergata, Roma, Italy
Leuk Lymphoma 51:95-106. 2010..03) was confirmed within ZAP-70 negative patients. Bcl-2 and CD71 can be considered as interesting progression indicators, which should be validated in an independent cohort of patients, to take timely therapeutic decisions in CLL... - Monitoring of minimal residual disease in acute myeloid leukemiaFrancesco Buccisano
Department of Biopatologia e Diagnostica per Immagini, Fondazione Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
Curr Opin Oncol 21:582-8. 2009..In the present review we will focus on the use of MPFC for monitoring of MRD, addressing the main technical and clinical issues... - Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemiaFrancesco Buccisano
Hematology, Fondazione Policlinico Tor Vergata, Viale Oxford 81, Rome, Italy
Blood 116:2295-303. 2010..001 for all comparisons). In AML, the integrated evaluation of baseline prognosticators and MRD improves risk-assessment and optimizes postremission therapy... - Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocationTiziana Ottone
Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
Genes Chromosomes Cancer 48:213-21. 2009..This study suggests a wider distribution in the human genome, and particularly at genes involved in chromosome translocations observed in t-AML, of DNA regions (hotspot) targeted by specific topo II drugs... - Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemiaMaria Ilaria Del Principe
Department of Hematology, , Ospedale S.Eugenio, Rome, Italy
Haematologica 89:1468-75. 2004..Concerning OS, ZAP-70, CD38 and age (< or > 60 years) were independent prognostic factors whereas sp53 showed only a tendency towards statistical significance... - Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA GroupFrancesco Lo-Coco
Department of Biopathology, University Tor Vergata of Rome, Via Montpellier 1, Rome, Italy
Blood 116:3171-9. 2010..Furthermore, our results highlight the role of cytarabine coupled to anthracyclines and ATRA during consolidation in the high-risk group... - Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemiaMaria Ilaria Del Principe
Cattedra di Ematologia, , Ospedale S Eugenio, Via Fiume Giallo, 430 MA, 00144 Roma, Rome, Italy
Blood 108:853-61. 2006..On this line, we recommend and are also interested in conducting a prospective randomized trial of early intervention versus observation for ZAP-70(+) patients... - CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling studyGiovanni Del Poeta
Department of Hematology, University Tor Vergata, Roma
Haematologica 97:279-87. 2012..Chronic lymphocytic leukemia is a clinically heterogeneous disease which needs novel prognostic parameters which can be easily and efficiently managed... - Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemiaAdriano Venditti
Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10 00144, Rome, Italy
Leuk Lymphoma 44:445-50. 2003..This review will focus on the state of art of MRD detection in acute myeloid leukemia (AML) using multidimensional flow cytometry (MFC), and will cover the laboratory and clinical aspects of this approach... - Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patientsMaria Christina Cox
Department of Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
Hematol J 4:263-70. 2003..Furthermore, we suggest FISH screening in failed, complex or suboptimal quality chromosome and specific FISH analysis for 5q, 7q, 12p, 17p, inv(16), t(11q23) in order to implement CBA accuracy... - An allele-specific rt-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemiaTiziana Ottone
Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
J Mol Diagn 10:212-6. 2008..This method is convenient and easily applicable in countries with limited resources and no access to real-time quantitative PCR-based technologies... - Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA lociSyed Khizer Hasan
Department of Biopathology, University of Rome Tor Vergata, Rome, Italy
Genes Chromosomes Cancer 49:726-32. 2010..Biased distribution of DNA breakpoints at both PML and RARA loci suggest the existence of different pathogenetic mechanisms in t-APL as compared with de novo APL... - Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaSergio Amadori
Tor Vergata University Hospital, Rome, Italy
Br J Haematol 149:376-82. 2010..The day 1 + 8 schedule, which was associated with the highest rate of DnP, met the statistical criteria to be selected as the preferred regimen for phase III comparison with best supportive care... - P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemiaMaria Ilaria Del Principe
Department of Haematology, University Tor Vergata, St Eugenio Hospital, Roma, Italy
Br J Haematol 121:730-8. 2003..Therefore, in adult ALL, PGP and bcl-2 represent sensitive indicators of clinical outcome, and potential targets of novel molecules aimed at overcoming chemoresistance and recurrent relapses... - Home care management of patients affected by hematologic malignancies: a reviewPasquale Niscola
Haematology Division, Tor Vergata University, Sant Eugenio Hospital, Via dell Umanesimo 10, 00144 Rome, Italy
Haematologica 91:1523-9. 2006..Therefore, all efforts should be made to overcome budget and administrative barriers and to ensure a more widespread use of this model of care... - Recombinant factor VIIa for the management of severe hemorrhages in patients with hematologic malignanciesPaolo De Fabritiis
Hematology, University Tor Vergata, St. Eugenio Hospital, Rome, Italy
Haematologica 89:243-5. 2004 - Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromesFrancesco Buccisano
Department of Biopatologia e Diagnostica per Immagini, Policlinico Tor Vergata and Ospedale S Eugenio, Rome, Italy
Eur J Haematol 80:107-14. 2008..An aberrant pattern of expression of L-selectin and intercellular adhesion molecule 1 (ICAM1) may characterise CD34+ blast cells in myelodysplastic syndromes (MDS) and secondary acute myeloid leukaemia (sAML)... - Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemiaRoberto Latagliata
Ematologia, Universita La Sapienza, Rome, Italy
Br J Haematol 143:681-9. 2008..DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses... - Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cellsGabriella Marfe
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
Exp Hematol 39:653-665.e6. 2011..Therefore, it is of great importance to understand the molecular mechanisms affecting cancer cell sensitivity and resistance to tyrosine kinase inhibitors... - Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patientsCarla Di Stefano
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
Cancer Sci 101:991-1000. 2010..These compounds constitute a promising therapeutic approach for patients with leukemia. They provide the basis for new strategies for an additional anticancer drug in leukemia therapies, especially when conventional ones fail... - Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemiaFrancesco Buccisano
Hematology, Fondazione Policlinico Tor Vergata, Rome, Italy
Blood 119:332-41. 2012..A comprehensive prognostic algorithm, generated by combining pretreatment cytogenetics/genetics and posttreatment MRD determination, should promote advances in development of personalized therapeutic approaches... - Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutationEmanuele Ammatuna
Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata via Montpellier, Rome, Italy
Ann Hematol 86:355-61. 2007..We conclude that this non-isotopic and rapid assay amenable to automation may be adopted in routine genetic diagnosis of CMDs as well as for initial screening of thrombocytosis of unknown nature... - Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patientsM Christina Cox
Department of Hematology, S'Eugenio Hospital, University of Tor Vergata, Rome, Italy
Am J Clin Pathol 122:298-306. 2004..Moreover, these cases should be readily distinguishable from 11q23+/MLL+ cases. We recommend that karyotypic analysis always be complemented by molecular or FISH methods to unravel MLL rearrangements... - Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosminTiziana Ottone
Department of Biopathology, University of Tor Vergata, Rome, Italy Laboratory of Neuro Oncohematology, Santa Lucia Foundation, Rome, Italy
Br J Haematol 161:533-40. 2013..Our data underscore the need of identifying low FLT3 ITD levels, which are probably associated with relapse in otherwise good prognosis CN-AML... - A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantationGiuseppe Gentile
Department of Cellular Biotechnology and Hematology, Univ, La Sapienza, Rome, Italy
BMC Infect Dis 6:167. 2006..Quantitative CMV-DNA PCR assay in plasma has been proposed to monitor CMV infection in SCT patients. We evaluated the clinical utility of pp65Ag and PCR assay in plasma of SCT recipients... - Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromesMaria Teresa Voso
Istituto di Ematologia, Universita Cattolica S Cuore, Rome, Italy
Clin Cancer Res 15:5002-7. 2009..We conducted a phase II multicenter study on the combination of the DNA-methyltransferase inhibitor 5-azacytidine (5-AZA) and the histone deacetylase inhibitor valproic acid (VPA) in patients with higher risk MDS... - Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantationAlessandra Picardi
Hematology, University Tor Vergata, St Eugenio Hospital, Rome, Italy
Hematol J 5:24-31. 2004..provide durable responses in patients not eligible for conventional SCT exploiting the graft-versus-malignancy effect and (3). is loaded by an high rate of fatal infections... - Monoclonal antibodies and immunoconjugates in acute myeloid leukemiaSergio Amadori
Department of Hematology, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy
Best Pract Res Clin Haematol 19:715-36. 2006..Whether or not monoclonal antibody therapy will improve disease outcome compared with conventional treatment regimens remains to be demonstrated by well-designed clinical trials... - Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximabRoberto Stasi
Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
Blood 112:1147-50. 2008..These results indicate that patients with active ITP have a defective T regulatory cell compartment that can be modulated by a B cell-targeted therapy... - Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemiaGiuseppe Cimino
Department of Cellular Biotechnology and Hematology, University of Rome La Sapienza, Rome, Italy
Cancer Res 66:8903-11. 2006..Further studies are needed to evaluate whether VPA-ATRA treatment by reprogramming differentiation of the leukemic clone might improve the response to chemotherapy in leukemia patients... - Bortezomib: efficacy comparisons in solid tumors and hematologic malignanciesTommaso Caravita
Myeloma Unit, Hematology Department, St Eugenio Hospital, Rome, Italy
Nat Clin Pract Oncol 3:374-87. 2006..This article summarizes the principal clinical trials of bortezomib and discusses its efficacy in solid and hematologic tumors... - Opioids in pain management of blood-related malignanciesPasquale Niscola
Hematology Division, Sant Eugenio Hospital, Tor Vergata University, Via dell Umanesimo 10, 00144, Rome, Italy
Ann Hematol 85:489-501. 2006..This article reviews the principles of opioid therapy and how opioids can be adapted for patients with pain due to haematological malignancies... - Molecular characterization of paediatric idiopathic hypereosinophiliaMaria Cristina Rapanotti
Department of Laboratory Medicine, Policlinico Tor Vergata, Rome, Italy
Br J Haematol 151:440-6. 2010..IGH rearrangement was observed to be a frequent molecular feature of pHES and may precede B-cell clonal expansion and evolution into B-cell malignancies in children... - Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemiaFrancesco Lo-Coco
Department of Biopathology, University Tor Vergata, Via Montpellier 1, 00161 Rome, Italy
Haematologica 93:1017-24. 2008..The aim of this study was to verify this prospectively in a large group of patients... - Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemiaSergio Amadori
Department of Hematology, Tor Vergata University Hospital, Rome, Italy
Curr Opin Hematol 15:95-100. 2008..This review addresses use of monoclonal antibodies and immunoconjugates to treat acute myeloid leukemia... - Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumorsAntonio Bruno
Department of Immunohematology, University Tor Vergata, Bambino Gesu Hospital, Rome, Italy
Transfus Apher Sci 26:103-10. 2002..Positive selection of CD34+ cells seems to be related to the quality of the apheresis products, particularly to the initial CD34+ cell and PLT content... - Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized studyLuciana Annino
Department of Cellular Biotechnology and Hematology, , via Benevento, 6-00161, Rome, Italy
Blood 99:863-71. 2002..Neither induction intensification nor early consolidation appeared to influence CCR and DFS duration. For the first time PDN pretreatment response proved to be a powerful factor predicting disease outcome in adult ALL patients... - Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosisSyed Khizer Hasan
Department of Biopathology, University of Tor Vergata, Rome, Italy
Blood 112:3383-90. 2008..This study further supports the presence of preferential sites of DNA damage induced by mitoxantrone in PML and RARA genes that may underlie the propensity to develop this subtype of leukemia after exposure to this agent... - PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cellsGabriella Marfe
Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
BMC Cancer 7:207. 2007..The objective of this study was to gain insight into the molecular mechanism of induced cell death (apoptosis) by PYRROLO [1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) series compounds, using human (K562) cells as a model... - Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLCEmanuele Ammatuna
Dipartimento di Biopatologia e Diagnostica per Immagini, University Tor Vergata, Rome, Italy
Clin Chem 51:2165-7. 2005 - Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopeniaRoberto Stasi
Department of Medical Sciences, Ospedale Regina Apostolorum, Albano Laziale, Rome, Italy
PLoS Med 3:e24. 2006..The long-term outcome of individuals with mild degrees of thrombocytopenia is unknown... - Clinical relevance of minimal residual disease detection in adult acute myeloid leukemiaAdriano Venditti
Cattedra di Ematologia, Universita di Roma Tor Vergata, Divisione di Ematologia, Osp S Eugenio, P le dell Umanesimo 10 00144, Rome, Italy
J Hematother Stem Cell Res 11:349-57. 2002..Thus, a MRD > or = 3.5 x 10(-4) leukemic cells at the end of consolidation strongly predicts relapse, and is significantly associated with MDR1-positive phenotype and intermediate/unfavorable cytogenetics... - Survival of elderly patients with acute myeloid leukemiaAlessandro Pulsoni
Dpt of Cellular Biotechnology and Hematology, La Sapienza University, Roma, Italy
Haematologica 89:296-302. 2004..We retrospectively evaluated the impact on survival of an aggressive versus a non-aggressive approach in 1005 patients aged >60 years registered in the database of the GIMEMA cooperative group... - Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cellsPaolo Corradini
Division of Hematology Bone Marrow Transplantation, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133 Milano, Italy
J Clin Oncol 22:2172-6. 2004..We performed a pilot study to investigate the role of reduced-intensity conditioning (RIC) followed by allogeneic stem-cell transplantation in relapsed or refractory PTCLs... - Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosagesFederico Pea
Department of Experimental and Clinical Pathology and Medicine, Medical School, Institute of Clinical Pharmacology and Toxicology, University of Udine, Udine, Italy
Clin Pharmacokinet 43:405-15. 2004....